Alkem Laboratories share price
NSE: ALKEMBSE: 539523Pharmaceuticals & BiotechnologyMid Cap
Alkem Laboratories Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2015
Last close ₹5,070.00down ₹8.00 (0.16%)BSE ₹5,074.15
Share price at the NSE close on 28 Oct 2026. Previous close ₹5,078.00.
28 Oct: open ₹5,076.00, high ₹5,079.00, low ₹5,003.50
52-week range of traded prices to 28 Oct 2026
₹4,811.00Low, 22 Oct 2026₹5,933.50High, 13 Jan 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹60,619 Cr164th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 28.10
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.39
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.05%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 16.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.11
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 78,88553.4% delivered
About Alkem Laboratories
Alkem Laboratories Limited is a Mumbai-based drug company that develops, makes and sells medicines, with India as its largest market.123 It also sells medicines in the United States, Europe, Australia, Latin America, Africa, the Middle East and Southeast Asia, and works in biosimilars (close copies of biological medicines), medical devices, consumer health and active pharmaceutical ingredients (the chemical raw material of medicines).1
In India it sells branded medicines for acute and chronic conditions, mainly anti-infectives, vitamins and nutrients, pain management and gastrointestinal medicines, and trade generics (generics sold to chemists through distributors, not promoted to doctors).13 The trade generics business was transferred to a subsidiary, Alkem Wellness Limited, effective 1 Oct 2025.2 Its consumer health business, ActivLife, is led by the A-to-Z brand portfolio, covering nutrition, women's health, paediatric care and everyday wellness, and its Alkem Activa division makes active pharmaceutical ingredients for its own use and for other companies.45 Enzene Biosciences, a subsidiary, sells biosimilars in India and runs a contract development and manufacturing business for other drug developers, in India and the United States.6 Alkem MedTech, a wholly owned subsidiary, makes orthopaedic and cardiovascular devices.78
It was incorporated in 1973.2 It acquired Ascend Laboratories, a US drug company, in 2010 and Enzene Biosciences in 2011, and completed its initial public offering in 2015.9 Through Alkem MedTech it acquired Bombay Ortho Industries, an orthopaedic implant maker in Rajkot, effective 16 Apr 2025.1011
Basudeo N Singh is Executive Chairman, and Managing Director Sandeep Singh is one of its promoters.1112
Alkem Laboratories key points
Results
- In the quarter to Jun 2026, revenue from operations was ₹37,402 million, up 10.9% from a year earlier, and EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹7,661 million, up 3.7%, a margin of 20.5%.13
- Net profit after non-controlling interest (excluding outside shareholders' share of subsidiaries' profit) fell 21.7% to ₹5,200 million in the quarter, which management attributed to tax.1415
- In the year to Mar 2026, consolidated revenue from operations was ₹147,123 million, up 13.5% from ₹129,645 million, and EBITDA was ₹30,052 million, a margin of 20.4%.16
- Consolidated net profit after tax, as the company presents it, for the year to Mar 2026 rose 6.3% to ₹23,018.0 million.17
Market position
- Market data put its India sales growth in the quarter to Jun 2026 at 13.2%, against 12.2% for the Indian pharmaceutical market. Chronic medicines (for long-term conditions) grew 17.9%, against 15.4% for the market.1819
- By the company's account, in the year to Mar 2026 it ranked 1st in India in anti-infectives, as for over 15 consecutive years, 2nd in vitamins and nutrients, and 3rd in pain medicines.20
- In the year to Mar 2026, 17 of its brands each had annual sales above ₹100 crore, together 52% of its India revenue.21
Where revenue comes from
Plants and capacity
- It has 20 manufacturing plants, 5 of them approved by the US Food and Drug Administration (US FDA): 18 in India across Sikkim, Baddi, Daman, Mandva, Ankleshwar and Pune, and the others in the United States.2627
- It has 3 research centres with more than 595 scientists, more than 14,500 medical representatives in India, and 11 central warehouses, 73 sales depots and more than 8,800 stockists (wholesalers that supply chemists).2825
- In its exchange filing of 2 Apr 2026, the company said its board had raised the planned investment in a new finished-medicines plant at Ujjain, Madhya Pradesh, from up to ₹533 crore to up to ₹1,036 crore.29
Biosimilars and contract manufacturing
- In the year to Mar 2026, Enzene launched a pertuzumab biosimilar for breast cancer in India and won European approval for its denosumab biosimilar for osteoporosis, its first in a major regulated market.30
- Enzene's 80,000 sq ft plant in Hopewell, New Jersey, a $50 million investment, opened in September 2025.6
- On its earnings call of 14 Aug 2026, the company said its US contract manufacturing business cost around ₹60 crore to run in the quarter and needs annual revenue of $25 million to $30 million to break even, not expected within 12 months.3132
Medical devices
- On 17 Jul 2026, the company said Alkem MedTech had completed its acquisition of Occlutech Holding AG, a company incorporated in Switzerland that makes minimally invasive cardiac implants. Alkem MedTech had said it intended to acquire at least 51% and up to 55%.3334
- By the company's account, Occlutech ranks 2nd in Europe in occluders (devices that close a hole in the heart) for atrial septal defect and patent foramen ovale, with over 200,000 implants.7
- On its earnings call of 14 Aug 2026, the company said it targets around ₹400 crore of Occlutech sales at breakeven EBITDA for about 8.5 months this financial year, below earlier guidance after integration delays.35
What the company expects
- On its earnings call of 14 Aug 2026, the company said it expects a gross margin (sales less cost of goods sold, as a share of sales) of 66.5% to 67% for the rest of the year.36
- On its earnings call of 14 Aug 2026, the company said it hopes to resolve the Daman plant's US FDA status within 6 to 12 months.37
Recent events
- On 6 Aug 2026, the company said the US FDA had classified its Amaliya, Daman plant as Official Action Indicated (regulatory action may follow) after an inspection; supply continues. On 14 Aug 2026, it said about 45% of its US revenue comes from this plant.3839
- On 30 Jun 2026, the company received income tax appeal orders that deleted disallowances of a tax deduction it had claimed for earlier years, involving tax of ₹660.77 crore.40
- As of its annual report of 29 Jul 2026, the company had appealed an income tax order of ₹3,333.3 million for assessment year 2023-24, which the tax department had set off against its tax credits.41
Last updated
All 41 sources, each with its page
- 1. Annual report, 29 Jul 2026, page 5
- 2. Annual report, 29 Jul 2026, page 154
- 3. Annual report, 29 Jul 2026, page 88
- 4. Annual report, 29 Jul 2026, page 5
- 5. Annual report, 29 Jul 2026, page 98
- 6. Annual report, 29 Jul 2026, page 92
- 7. Annual report, 29 Jul 2026, page 95
- 8. Annual report, 29 Jul 2026, page 6
- 9. Investor presentation, 14 Aug 2026, page 21
- 10. Annual report, 29 Jul 2026, page 106
- 11. Annual report, 29 Jul 2026, page 80
- 12. Earnings call, 14 Aug 2026, page 10
- 13. Investor presentation, 14 Aug 2026, page 9
- 14. Investor presentation, 14 Aug 2026, page 10
- 15. Earnings call, 14 Aug 2026, page 4
- 16. Annual report, 29 Jul 2026, page 102
- 17. Annual report, 29 Jul 2026, page 106
- 18. Investor presentation, 14 Aug 2026, page 12
- 19. Investor presentation, 14 Aug 2026, page 3
- 20. Annual report, 29 Jul 2026, page 88
- 21. Annual report, 29 Jul 2026, page 88
- 22. Investor presentation, 14 Aug 2026, page 2
- 23. Investor presentation, 14 Aug 2026, page 3
- 24. Investor presentation, 14 Aug 2026, page 14
- 25. Annual report, 29 Jul 2026, page 6
- 26. Annual report, 29 Jul 2026, page 12
- 27. Annual report, 29 Jul 2026, page 43
- 28. Annual report, 29 Jul 2026, page 100
- 29. Exchange filing, 2 Apr 2026, page 1
- 30. Annual report, 29 Jul 2026, page 92
- 31. Earnings call, 14 Aug 2026, page 5
- 32. Earnings call, 14 Aug 2026, page 8
- 33. Exchange filing, 17 Jul 2026, page 1
- 34. Exchange filing, 13 Feb 2026, page 3
- 35. Earnings call, 14 Aug 2026, page 6
- 36. Earnings call, 14 Aug 2026, page 13
- 37. Earnings call, 14 Aug 2026, page 12
- 38. Exchange filing, 6 Aug 2026, page 1
- 39. Earnings call, 14 Aug 2026, page 7
- 40. Exchange filing, 1 Jul 2026, page 2
- 41. Annual report, 29 Jul 2026, page 330
Results
Consolidated; ₹ crore.Alkem Laboratories quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +13.4%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −5.6%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹3,740 Crup 3.80%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹521 Crup 107.47%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 13.9%
Revenue by quarter
Peak revenue ₹4,001 Cr, quarter to Sep 2025; lowest ₹3,144 Cr, quarter to Mar 2025
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 | 3,737 | 3,603 | 3,740 |
| Net profit | 702 | 641 | 322 | 668 | 779 | 653 | 251 | 521 |
| Net margin | 20.6% | 19.0% | 10.3% | 19.8% | 19.5% | 17.5% | 7.0% | 13.9% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹14,712 Crup 13.48%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹2,351 Crup 6.13%
- Net margin
- 16.0%
Revenue by year
Peak revenue ₹14,712 Cr, year to Mar 2026; lowest ₹5,853 Cr, year to Mar 2017
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5,853 | 6,431 | 7,357 | 8,344 | 8,865 | 10,634 | 11,599 | 12,668 | 12,965 | 14,712 |
| Net profit | 905 | 638 | 774 | 1,149 | 1,618 | 1,680 | 1,007 | 1,811 | 2,215 | 2,351 |
| Net margin | 15.5% | 9.9% | 10.5% | 13.8% | 18.2% | 15.8% | 8.7% | 14.3% | 17.1% | 16.0% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, The Company is exclusively engaged in pharmaceutical business, which carries all its revenue.
Valuation
Today, against the company's own history.Alkem Laboratories PE ratio and valuation
Price to earnings
At or below today's level on 44% of 2,215 trading days since Nov 2016.
LowestHighest
Its median28.48Industry median28.03
Price to book
At or below today's level on 23% of 1,978 trading days since Nov 2018.
LowestHighest
Its median4.89Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 79% of 2,478 trading days over the last 10 years.
LowestHighest
Its median0.86%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +9.5% | +6.3% | +2.1% | 1.0% |
| 3 years | +16.9% | +32.7% | −12.6% | 0.9% |
| 5 years | +14.9% | +7.7% | +5.7% | 1.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 3 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2023.
Mutual fund holdings
201 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 100 of the 130 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 2 more funds filed their first portfolio on record, holding it.All 201 funds holding Alkem Laboratories
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 3
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 6
- AddedAdded. Funds that held more shares than at the end of the month before.
- 103
- CutCut. Funds that held fewer shares than at the end of the month before.
- 27
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 60
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 11
| Fund | |||
|---|---|---|---|
 HDFC Mid Cap FundHDFC Mutual Fund | 33,88,530 | 1.72% | ₹1,749.7 Cr |
 ICICI Prudential Multi Asset Allocation FundICICI Prudential Mutual Fund | 15,49,513 | 0.95% | ₹800.1 Cr |
 SBI Large & Midcap FundSBI Mutual Fund | 14,76,712 | 1.88% | ₹762.5 Cr |
 Nippon India Growth Mid Cap FundNippon India Mutual Fund | 12,30,397 | 1.27% | ₹635.3 Cr |
 Axis Midcap FundAxis Mutual Fund | 8,92,035 | 1.37% | ₹460.6 Cr |
 DSP Large & Mid Cap FundDSP Mutual Fund | 6,55,901 | 1.96% | ₹338.7 Cr |
| DSP Midcap FundDSP Mutual Fund | 6,45,036 | 1.71% | ₹333.1 Cr |
| ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 6,39,791 | 4.81% | ₹330.4 Cr |
 Kotak Arbitrage FundKotak Mahindra Mutual Fund | 5,64,500 | 0.39% | ₹291.5 Cr |
| HDFC Balanced Advantage FundHDFC Mutual Fund | 5,59,771 | 0.28% | ₹289.0 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Alkem Laboratories insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade
- Others: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Alkem Laboratories competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Alkem Laboratories in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Mankind PharmaMANKIND | 1,02,848 | 45.74 | 5.85 | +13.3% | +28.4% | 13.7% | 13.6% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 94,638 | 25.49 | 2.50 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
 LupinLUPIN | 90,210 | 16.32 | 4.02 | +28.2% | +49.5% | 27.9% | 28.2% | 0.91% |
 Glenmark PharmaceuticalsGLENMARK | 64,912 | 36.10 | 6.17 | +32.9% | +138.4% | 18.6% | 39.8% | 0.11% |
 BioconBIOCON | 57,153 | 115.39 | 1.68 | +9.8% | +28.6% | 1.8% | 2.9% | 0.14% |
 Abbott IndiaABBOTINDIA | 55,833 | 34.58 | 11.69 | +6.3% | +11.2% | 35.9% | 39.6% | 2.50% |
 Gland PharmaGLAND | 50,312 | 44.57 | 4.86 | +17.6% | +46.5% | 11.6% | 12.4% | 0.66% |
 IPCA LaboratoriesIPCALAB | 48,978 | 37.39 | 6.07 | +10.6% | +68.2% | 17.4% | 17.6% | 0.31% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Alkem Laboratories dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹53.00 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 7 Aug 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹10.00 |
| 20 Feb 2026 | Interim | ₹43.00 |
| 8 Aug 2025 | Final | ₹8.00 |
| 14 Feb 2025 | Interim | ₹37.00 |
| 9 Aug 2024 | Final | ₹5.00 |
| 16 Feb 2024 | Interim | ₹35.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Alkem Laboratories announcements
Oct 2026
Sep 2026
24 Sep · Management
24 Sep · Management
23 Sep · Analysts
Alkem Laboratories share price by year
Each calendar year to 2025.Alkem Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 5,506.50 | −2.3% | 5,773.00 | 4,563.70 |
| 2024 | 5,633.90 | +8.3% | 6,366.25 | 4,616.35 |
| 2023 | 5,202.60 | +73.1% | 5,202.60 | 3,000.70 |
| 2022 | 3,004.70 | −17.1% | 3,736.55 | 2,902.75 |
| 2021 | 3,624.05 | +23.8% | 4,003.10 | 2,574.80 |
| 2020 | 2,926.20 | +45.3% | 2,981.95 | 2,082.85 |
| 2019 | 2,013.90 | +3.3% | 2,117.05 | 1,669.00 |
| 2018 | 1,949.20 | −11.5% | 2,323.60 | 1,745.45 |
| 2017 | 2,201.90 | +35.2% | 2,211.30 | 1,622.25 |
| 2016 | 1,628.65 | +9.7% | 1,844.85 | 1,186.45 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 4,990.00 | 5,166.00 | 4,963.00 | 5,078.00 | 5,069.51 | 1,66,281 | 43.3% |
| 26 Oct 2026 | 4,960.00 | 5,030.00 | 4,878.50 | 5,030.00 | 4,966.40 | 69,617 | 47.3% |
| 23 Oct 2026 | 4,975.50 | 5,019.50 | 4,877.00 | 4,947.00 | 4,928.84 | 54,982 | 51.0% |
| 22 Oct 2026 | 4,982.00 | 5,015.00 | 4,811.00 | 5,013.50 | 4,955.69 | 49,335 | 33.6% |
| 21 Oct 2026 | 4,979.00 | 5,050.50 | 4,891.50 | 5,015.00 | 4,947.54 | 2,79,107 | 70.5% |
| 19 Oct 2026 | 5,042.50 | 5,099.50 | 4,975.50 | 5,004.00 | 5,025.21 | 95,218 | 59.8% |
| 16 Oct 2026 | 5,138.50 | 5,147.00 | 5,042.00 | 5,050.00 | 5,065.25 | 1,60,798 | 74.0% |
| 15 Oct 2026 | 5,210.00 | 5,249.00 | 5,120.50 | 5,120.50 | 5,171.49 | 59,913 | 54.8% |
| 14 Oct 2026 | 5,259.00 | 5,270.50 | 5,171.00 | 5,201.00 | 5,205.82 | 79,840 | 62.9% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- ALKEM
- BSE code
- 539523
- ISIN
- INE540L01014
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.alkemlabs.com
- CIN
- L00305MH1973PLC174201
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1973
- Registered office
- Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai 400013, Maharashtra
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In BSE 200, Nifty 500, BSE 500, Nifty Midcap 150, BSE 150 MidCap Index, BSE MidCap